China's BYD, Tsingshan scrap plans for Chile lithium plants
Chinese automaker BYD and metals group
Tsingshan
are backing out of multi-million dollar plans to build lithium cathode plants in Chile, the country's economic development agency said on Wednesday.
The retreat by the two huge Chinese companies is a blow to Chile's aim to develop more domestic processing of lithium, a key metal for
electric vehicle batteries
. Chile is the world's no. 2 lithium producer.
Both projects were hit by plunging lithium prices, said government economic development agency
Corfo
, which in 2023 had tapped BYD and Tsingshan for a preferential lithium price deal as part of its efforts to spur investment in Chile.
"The companies selected by Corfo have been affected in their investment decisions by the global market conditions, which have shown a sharp drop in prices," Corfo said in a statement.
Tsingshan told Reuters it has withdrawn plans for a $233 million project to produce 120,000 metric tons of
lithium iron phosphate
(LFP). Chile's national assets ministry told Reuters that BYD filed an intent to withdraw its plans in January.
BYD, the world's biggest maker of electric cars, declined to comment. BYD last year flagged delays to a planned $290 million plant, which was expected to produce 50,000 metric tons per year of LFP for cathodes.
Chilean newspaper Diario Financiero first reported the scrapped investments.
Chile's effort in 2018 to encourage lithium-related investments via a pricing deal also fell apart. Chilean chemical company Molymet, China's Sichuan Fulin Transportation Group Co , and a joint venture between Korean firms Posco and Samsung for various reasons withdrew their plans.
Tsingshan and BYD would have had access to preferential prices of lithium produced by Chilean miner SQM through 2030, a timeframe that Corfo said also may have influenced the withdrawal of the projects.
In addition, Corfo said Tsingshan had wanted to assign the project development to a unit of the company that had not participated in the bidding process, which Corfo said was not possible.
Corfo last week opened a second bidding process for a similar scheme, this time to provide a purchasing deal with U.S. lithium producer Albemarle through 2043 for companies that commit to lithium-related projects.
Albemarle and the selected investors will be able to use an "alternative form" to determine a price agreement, Corfo said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
an hour ago
- India Today
5 years since Galwan, how India has fortified border with reforms and roads
Five years ago, on June 15, 2020, India lost 20 soldiers in the Galwan Valley clash with China in Eastern Ladakh - an event that not only redefined India-China ties but also triggered a series of reforms in India's defence posture and strategic planning along the Line of Actual Control (LAC).The Galwan clash, which saw Indian troops retaliate without firearms under existing protocols, also caused significant casualties on the Chinese side and marked a complete breakdown in trust between the two the years since, India has significantly restructured its military preparedness, reinforced border infrastructure, and intensified diplomatic engagements. The Indian armed forces enhanced their presence across the LAC, especially in Eastern Ladakh, with rapid deployment of troops and high-altitude warfare equipment. Emergency procurement provisions were invoked to expedite defence acquisitions, including surveillance systems, UAVs, artillery, and medical equipment for extreme terrain. The Galwan incident became a catalyst for infrastructure expansion. The Union Budget for FY 2025-26 allocated Rs 6.81 lakh crore to the Ministry of Defence, a 9.53% increase from the previous year. Of this, Rs 7,146 crore was set aside for the Border Roads Organisation (BRO), which completed 75 projects worth Rs 2,236 crore in 2024 include roads and bridges in strategic regions like Ladakh, Arunachal Pradesh, Sikkim, and Himachal Pradesh. BRO's earlier achievements included the world's highest motorable road at Umling La (19,024 feet) and ongoing development of the Nyoma Airfield and Shinku La last five years have also seen the LAC's digital landscape transformed. Remote villages in Ladakh, including Galwan and Demchok, were connected to 4G networks under a joint initiative by the Indian Army and Bharti Airtel. This step opened up access to telemedicine, digital education, and government schemes, with the potential to improve tourism and local the diplomatic front, over 30 rounds of talks have taken place since 2020. India and China have conducted 21 rounds of Corps Commander-level discussions and multiple Working Mechanism for Consultation & Coordination (WMCC) meetings. Disengagement has occurred at several friction points: Galwan in July 2020, Pangong Tso in February 2021, PP17A (Gogra-Hot Springs) in August 2021, PP15 in September 2022, and most recently, at Demchok and Depsang in October diplomatic meetings also continued. On June 12, 2025, Foreign Secretary Vikram Misri met Chinese Vice Foreign Minister Sun Weidong in Delhi to discuss bilateral ties, people-centric engagement, and reopening direct air services. Talks included progress on resuming hydrological data sharing and finalising an updated air services agreement. Visa facilitation, media exchanges, and commemorations of 75 years of India-China diplomatic relations were also partial disengagement, India remains cautious. 'Galwan was a turning point,' says Maj Gen Ashok Kumar (Retd), Director General of Centre for Joint Warfare Studies. 'It shattered all trust in Chinese political and military leadership. India's vigilance along the LAC is now permanent.'India's response post-Galwan is widely seen as a comprehensive shift—not only in defence and diplomacy but in redefining the strategic calculus of border management. The clash, now etched in national memory, has ensured that preparedness, infrastructure, and international positioning are not reactive but Watch
Mint
an hour ago
- Mint
China's Biotech Moment Ignites a 60% Stock Rally That Beats AI
China's biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds are tipping further gains. The Hang Seng Biotech Index has surged more than 60% since the start of January amid investor enthusiasm over a pair of billion-dollar deals involving foreign firms licensing Chinese drugs. Share gains at two highly anticipated listings of local producers have further burnished the sector's appeal. 'China biotech is no longer just an emerging story — unlike 10 years ago — it is now a disruptive force reshaping global drug innovation,' said Yiqi Liu, senior investment analyst at Exome Asset Management LLC in New York. 'The science is real, the economics are compelling, and the pipeline is starting to deliver.' The surge in China-listed biotech firms is further evidence that the mainland is becoming a center for global innovation. The rally in the sector this year outpaces the 17% gain in China's tech stocks that was driven by the release of DeepSeek's breakthrough artificial-intelligence app in January. A major reason for the share gains were two mega-sized licensing deals. Pfizer Inc. said on May 19 it had agreed to pay a record $1.25 billion to license an experimental cancer drug from China's 3SBio Inc., and also invest $100 million in the firm's shares. Two weeks later, Bristol-Myers Squibb Co. said it would pay Germany's BioNTech SE as much as $11.5 billion to license a cancer drug that BioNTech had itself licensed from China's Biotheus Inc. in 2023. Some of the gains in biotech shares this year have been stratospheric. 3SBio has surged 283%, topping a Bloomberg gauge of global biotech stocks. RemeGen Co., which develops antibody drugs, has climbed more than 270% after saying it was approached by multinational pharmaceutical firms for potential licensing deals. China's growing influence through pharmaceutical mergers and acquisitions and deal-making is also causing investors to take note. In the first quarter alone, the value of such deals involving local players doubled from the year before to $36.9 billion. That amount made up more than half the global total of $67.5 billion. Chinese biotech companies are having 'their own DeepSeek moment,' said Dong Chen, chief Asia strategist at Pictet Wealth Management in Hong Kong. There is more upside from here, he said. Investor interest in biotech — which involves the use living organisms to make medicines and other products — can be seen in the big runup at recent initial public offerings. Shares of Duality Biotherapeutics Inc., which develops cancer treatments, more than doubled on their first day of trading in Hong Kong on April 15. Jiangsu Hengrui Pharmaceuticals Co., the nation's largest drugmaker by market value, saw its stock jump 25% on debut May 23, even after being issued at the top end of the marketed range. Duality has now risen 189% since its IPO, while Jiangsu has gained 31%. Still, some say the rally may be getting stretched. 'Bears, mostly healthcare specialists, plan to take profit at this point, and some investors prefer the healthcare laggers with capability of constant dividend payout and stable revenue growth,' Bank of America Corp. analysts including Ethan Cui in Hong Kong wrote in a research note this month. Some investors also said they viewed the rush of recent licensing deals as a one-off, and they were refusing to grant valuation multiples to the companies, the analysts wrote. While the recent ratcheting up of trade tensions between the US and China has been a negative for many mainland firms, it's also resulted in talent flowing back to China and creating more research-and-development capability, according to Nicholas Chui, a Chinese equity fund manager at Franklin Templeton in Hong Kong. Jefferies is also bullish, saying the increase in US tariffs is unlikely to prove an obstacle to Chinese biotech firms. Many of the Chinese biotech companies already have US partners and are therefore considered as service providers rather than product exporters, said Cui Cui, head of Asia healthcare research at the company in New York. With assistance from Dong Lyu. This article was generated from an automated news agency feed without modifications to text.
New Indian Express
5 hours ago
- New Indian Express
Rare earth magnet crisis: A dent in Indian auto sector
The Indian automotive sector, particularly its electric vehicle (EV) segment, is grappling with a looming supply-chain disruption due to China's stringent export restrictions on rare earth magnets. These low-cost yet functionally critical components are indispensable for modern vehicles, and their scarcity threatens to impact production, new model launches, and the industry's ambitious growth trajectory. What are Rare Earth Magnets and why are they critical? Rare earth magnets are made from alloys of rare earth elements. They are integral to Permanent Magnet Synchronous Motors (PMSMs), which are widely used in EVs for their high torque, energy efficiency, and compact size. Hybrid vehicles also rely on them for efficient propulsion. In Internal Combustion Engine (ICE) vehicles, their use is primarily limited to electric power steering and other motorized systems. Elements like Dysprosium (Dy), Terbium (Tb), Neodymium (Nd), and Praseodymium (Pr) are crucial for these magnets, especially in high-performance applications. China's dominance and new restrictions China is the world's dominant exporter of rare earth magnets, controlling over 70% of global Rare Earth Element (REE) production and over 90% of refining capacity. In April 2025, Beijing imposed stricter export controls on seven rare earth elements and finished magnets, mandating export licenses. This revised framework demands detailed end-use disclosures and client declarations, including confirmation that products will not be used in defense or re-exported to the US. This added scrutiny has prolonged the clearance process to at least 45 days, leading to significant delays and a growing backlog that is tightening global supply chains. Impact on the Indian automotive sector India, which sourced over 80% of its approximately 540 tonnes of magnet imports from China last fiscal year, has begun to feel the pinch. By the end of May 2025, despite nearly 30 import requests from Indian companies being endorsed by the Indian government, none had received approval from Chinese authorities, and no shipments had arrived.
